Literature DB >> 22740994

Fibronectin 1 protein expression in clear cell renal cell carcinoma.

S Steffens1, A J Schrader, Gesa Vetter, H Eggers, H Blasig, J Becker, M A Kuczyk, J Serth.   

Abstract

Fibronectin 1 (FN1) is a glycoprotein that is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defenses and metastasis. The aim of this study was to elucidate the FN1 protein expression in renal cell carcinoma (RCC) and to determine its potential prognostic relevance. A total of 270 clear cell RCC tissue specimens were collected from patients undergoing surgery for renal tumors. Biomarker expression was determined by immunohistochemistry and correlated with clinical variables. Survival analysis was carried out for 153 patients with complete follow-up data and pathologically proven clear cell carcinoma of the kidney. The follow-up group had a mean follow-up period of 83.8 months (IQR 26.2-136.2 months). The calculated median 5-year overall and tumor-specific survival rate of all 153 evaluable patients was 66.6 and 71.0%, respectively. A higher disease-related mortality rate was observed among patients with cytoplasmic FN1 expression (41.3 vs. 24.7%, p=0.039, Fisher's exact test). No significant correlation was found between FN1 staining and patient characteristics such as age, gender, tumor differentiation and visceral metastasis. However, there was a trend for FN1 expression and correlation with tumor stage and lymph node metastasis (p=0.085 and p=0.203; respectively). The Kaplan-Meier analysis revealed significant differences in the 5-year tumor-specific survival for patients with and without cytoplasmic FN1 expression (64.8 vs. 77.7%; p=0.035, log-rank test). However, results of the multivariate Cox regression analysis showed that FN1 expression was not an independent marker of either overall or tumor-specific survival. In conclusion, FN1 protein expression in RCC is associated with a higher disease-related mortality rate, indicating a possible role in RCC progression. Therefore, our data on FN1 encourage further investigations to determine the role of FN1 in RCC.

Entities:  

Year:  2012        PMID: 22740994      PMCID: PMC3362387          DOI: 10.3892/ol.2012.566

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  Extracellular matrix and integrin composition of the normal bladder wall.

Authors:  C B Wilson; J Leopard; D A Cheresh; R M Nakamura
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

2.  Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients.

Authors:  Ujjwala M Warawdekar; Surekha M Zingde; K S N Iyer; P Jagannath; Ashok R Mehta; Narendra G Mehta
Journal:  Clin Chim Acta       Date:  2006-05-30       Impact factor: 3.786

3.  Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.

Authors:  H Takayasu; H Horie; E Hiyama; T Matsunaga; Y Hayashi; Y Watanabe; S Suita; M Kaneko; F Sasaki; K Hashizume; T Ozaki; K Furuuchi; M Tada; N Ohnuma; A Nakagawara
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

4.  Changes in gene expression during progression of ovarian carcinoma.

Authors:  J Tapper; E Kettunen; W El-Rifai; M Seppälä; L C Andersson; S Knuutila
Journal:  Cancer Genet Cytogenet       Date:  2001-07-01

5.  The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.

Authors:  Hossein Tezval; Steffanie Jurk; Farahnaz Atschekzei; Jürgen Serth; Markus A Kuczyk; Axel S Merseburger
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

6.  Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer.

Authors:  Sandra Waalkes; Faranaz Atschekzei; Mario W Kramer; Jörg Hennenlotter; Gesa Vetter; Jan U Becker; Arnulf Stenzl; Axel S Merseburger; Andres J Schrader; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Cancer       Date:  2010-09-22       Impact factor: 4.430

7.  Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.

Authors:  Axel S Merseburger; Mario W Kramer; Jörg Hennenlotter; Perikles Simon; Judith Knapp; Jörg T Hartmann; Arnulf Stenzl; Jürgen Serth; Markus A Kuczyk
Journal:  Prostate       Date:  2008-01-01       Impact factor: 4.104

Review 8.  Fibronectin and integrins in invasion and metastasis.

Authors:  S K Akiyama; K Olden; K M Yamada
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

9.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

10.  RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.

Authors:  Inga Peters; Kristina Rehmet; Nadine Wilke; Markus A Kuczyk; Jörg Hennenlotter; Tyark Eilers; Stefan Machtens; Udo Jonas; Jürgen Serth
Journal:  Mol Cancer       Date:  2007-07-16       Impact factor: 27.401

View more
  32 in total

1.  Cellular fibronectin 1 promotes VEGF-C expression, lymphangiogenesis and lymph node metastasis associated with human oral squamous cell carcinoma.

Authors:  Yoshihiro Morita; Kenji Hata; Masako Nakanishi; Tetsuji Omata; Nobuo Morita; Yoshiaki Yura; Riko Nishimura; Toshiyuki Yoneda
Journal:  Clin Exp Metastasis       Date:  2015-08-29       Impact factor: 5.150

Review 2.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

3.  c-Met in chromophobe renal cell carcinoma.

Authors:  Franziska Erlmeier; Philipp Ivanyi; Arndt Hartmann; Michael Autenrieth; Max Wiedemann; Wilko Weichert; Sandra Steffens
Journal:  Med Oncol       Date:  2016-12-29       Impact factor: 3.064

4.  PD-L2: A prognostic marker in chromophobe renal cell carcinoma?

Authors:  Franziska Erlmeier; Wilko Weichert; Michael Autenrieth; Max Wiedemann; Andres Jan Schrader; Arndt Hartmann; Philipp Ivanyi; Sandra Steffens
Journal:  Med Oncol       Date:  2017-03-28       Impact factor: 3.064

5.  Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer.

Authors:  Weiwei Liang; Zhiwei Xie; Weiling Cui; Yan Guo; Lijuan Xu; Jueheng Wu; Hongyu Guan
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-10       Impact factor: 4.553

6.  Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.

Authors:  Christina A von Roemeling; Derek C Radisky; Laura A Marlow; Simon J Cooper; Stefan K Grebe; Panagiotis Z Anastasiadis; Han W Tun; John A Copland
Journal:  Cancer Res       Date:  2014-06-24       Impact factor: 12.701

7.  N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications.

Authors:  Ruth Hüttenhain; Silvia Surinova; Reto Ossola; Zhi Sun; David Campbell; Ferdinando Cerciello; Ralph Schiess; Damaris Bausch-Fluck; George Rosenberger; Jingchung Chen; Oliver Rinner; Ulrike Kusebauch; Marián Hajdúch; Robert L Moritz; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2013-02-13       Impact factor: 5.911

8.  Decellularization of intact tissue enables MALDI imaging mass spectrometry analysis of the extracellular matrix.

Authors:  Megan Gessel; Jeffrey M Spraggins; Paul Voziyan; Billy G Hudson; Richard M Caprioli
Journal:  J Mass Spectrom       Date:  2015-11       Impact factor: 1.982

9.  Identification of therapeutic targets for breast cancer using biological informatics methods.

Authors:  Xuejian Liu; Yongzhen Ma; Wenchuan Yang; Xia Wu; Lihua Jiang; Xiangli Chen
Journal:  Mol Med Rep       Date:  2015-03-27       Impact factor: 2.952

10.  Reduction of microRNA-206 contributes to the development of bronchopulmonary dysplasia through up-regulation of fibronectin 1.

Authors:  Xiaoying Zhang; Jing Xu; Junjie Wang; Ludwig Gortner; Sheng Zhang; Xiujuan Wei; Jie Song; Yupei Zhang; Qiuping Li; Zhichun Feng
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.